MA26837A1 - Heterocycles azotes bicycliques heteroalky-lamino substitues en tant qu'inhibiteurs de kinase de proteine p38. - Google Patents

Heterocycles azotes bicycliques heteroalky-lamino substitues en tant qu'inhibiteurs de kinase de proteine p38.

Info

Publication number: MA26837A1
Authority: MA; Morocco
Prior art keywords: heteroalky; lamino; protein kinase; kinase inhibitors; nitrogen heterocycles
Prior art date: 1999-10-21

Application number

MA26612A

Other languages

English (en)

Inventor

James Patrick Dunn

David Michael Goldstein

William Harris

Ian Edward David Smith

Teresa Rosanne Welch

Lawrence Emerson Fisher

Christopher Huw Hill

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-21

Filing date

2002-04-19

Publication date

2004-12-20

2002-04-19 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2004-12-20 Publication of MA26837A1 publication Critical patent/MA26837A1/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Virology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Oncology (AREA)
Dermatology (AREA)
Hematology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Tropical Medicine & Parasitology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)

MA26612A 1999-10-21 2002-04-19 Heterocycles azotes bicycliques heteroalky-lamino substitues en tant qu'inhibiteurs de kinase de proteine p38. MA26837A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US16080399P	1999-10-21	1999-10-21
US21374300P	2000-06-22	2000-06-22

Publications (1)

Publication Number	Publication Date
MA26837A1 true MA26837A1 (fr)	2004-12-20

Family

ID=26857240

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA26612A MA26837A1 (fr)	1999-10-21	2002-04-19	Heterocycles azotes bicycliques heteroalky-lamino substitues en tant qu'inhibiteurs de kinase de proteine p38.

Country Status (26)

Country	Link
US (1)	US6451804B1 (fr)
EP (1)	EP1228070B1 (fr)
JP (1)	JP3961830B2 (fr)
KR (1)	KR100523120B1 (fr)
CN (1)	CN1171889C (fr)
AR (1)	AR026084A1 (fr)
AT (1)	ATE353329T1 (fr)
AU (1)	AU776250B2 (fr)
BR (1)	BR0015243A (fr)
CA (1)	CA2388142C (fr)
CZ (1)	CZ20021744A3 (fr)
DE (1)	DE60033307T2 (fr)
ES (1)	ES2280247T3 (fr)
HR (1)	HRP20020328A2 (fr)
HU (1)	HUP0203564A3 (fr)
IL (1)	IL149100A0 (fr)
MA (1)	MA26837A1 (fr)
MX (1)	MXPA02003950A (fr)
NO (1)	NO20021781L (fr)
NZ (1)	NZ518119A (fr)
PE (1)	PE20010758A1 (fr)
PL (1)	PL357502A1 (fr)
RU (1)	RU2265606C2 (fr)
TR (1)	TR200201057T2 (fr)
WO (1)	WO2001029042A1 (fr)
YU (1)	YU29102A (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EE200000706A (et)	1998-05-26	2002-06-17	Warner-Lambert Company	Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid
CN1293078C (zh) *	2002-04-03	2007-01-03	霍夫曼-拉罗奇有限公司	咪唑并稠合化合物
MXPA04010267A (es) *	2002-04-19	2005-02-03	Smithkline Beecham Corp	Compuestos novedosos.
ES2278170T3 (es)	2002-07-09	2007-08-01	BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG	Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
PA8577501A1 (es)	2002-07-25	2004-02-07	Warner Lambert Co	Inhibidores de quinasas
RU2324695C2 (ru) *	2002-08-06	2008-05-20	Ф.Хоффманн-Ля Рош Аг	6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38
US7084270B2 (en) *	2002-08-14	2006-08-01	Hoffman-La Roche Inc.	Pyrimido compounds having antiproliferative activity
US7112676B2 (en)	2002-11-04	2006-09-26	Hoffmann-La Roche Inc.	Pyrimido compounds having antiproliferative activity
TW200413381A (en)	2002-11-04	2004-08-01	Hoffmann La Roche	Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
ATE427951T1 (de) *	2002-11-18	2009-04-15	Hoffmann La Roche	Diazinopyrimidine und ihre verwendung als proteinkinaseinhibitoren
CN100497339C (zh) *	2003-04-10	2009-06-10	霍夫曼-拉罗奇有限公司	嘧啶并化合物
BRPI0413005A (pt)	2003-07-29	2006-09-26	Irm Llc	compostos e composições como inibidores da proteìna cinase
US20060035893A1 (en)	2004-08-07	2006-02-16	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
CN1984914A (zh)	2004-08-31	2007-06-20	霍夫曼-拉罗奇有限公司	7－氨基－3－苯基－二氢嘧啶并[4,5－d]嘧啶酮的酰胺衍生物、其制备和作为蛋白激酶抑制剂的应用
WO2006024486A2 (fr)	2004-08-31	2006-03-09	F. Hoffmann-La Roche Ag	Derives amide de 3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, leur fabrication et leur utilisation en tant qu'agents pharmaceutiques
WO2006038112A1 (fr) *	2004-10-01	2006-04-13	Warner-Lambert Company Llc	Utilisation d'inhibiteurs de kinases pour favoriser la neochondrogenese
EP1831215A1 (fr) *	2004-11-23	2007-09-12	Ranbaxy Laboratories Limited	Pyrido[2, 3-d]pyrimidines utilisees comme agents anti-inflammatoires
PE20060777A1 (es)	2004-12-24	2006-10-06	Boehringer Ingelheim Int	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1846403A1 (fr) *	2005-02-02	2007-10-24	Ranbaxy Laboratories Limited	Derives azabicyclo utilises comme agents anti-inflammatoires
CN101341116A (zh) *	2005-12-22	2009-01-07	巴斯夫欧洲公司	制备o-烷基化环状氨基醇的方法
ES2329419T3 (es)	2006-01-31	2009-11-25	F. Hoffmann-La Roche Ag	7h-pirido(3,4-d)pirimidin-8-onas, su preparacion y uso como inhibidores de proteinas cinasas.
ES2301380B1 (es)	2006-08-09	2009-06-08	Laboratorios Almirall S.A.	Nuevos derivados de 1,7-naftiridina.
ES2320955B1 (es)	2007-03-02	2010-03-16	Laboratorios Almirall S.A.	Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2329639B1 (es)	2007-04-26	2010-09-23	Laboratorios Almirall S.A.	Nuevos derivados de 4,8-difenilpoliazanaftaleno.
RU2340327C1 (ru) *	2007-05-03	2008-12-10	Лев Давидович Раснецов	Офтальмологический гель и способ его приготовления
EP1992344A1 (fr)	2007-05-18	2008-11-19	Institut Curie	P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
GB2452696B (en) *	2007-08-02	2009-09-23	Cambridge Entpr Ltd	3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
EP2108641A1 (fr) *	2008-04-11	2009-10-14	Laboratorios Almirall, S.A.	Nouveaux dérivés substitués de spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one et leur utilisation comme ihibiteurs de p38 mitogen-activated kinase
EP2113503A1 (fr)	2008-04-28	2009-11-04	Laboratorios Almirall, S.A.	Nouveaux dérivés d'indolin-2-one substitués et leur utilisation comme inhibiteurs de p38 mitogen-activated kinase
PT2484661T (pt)	2009-09-30	2017-06-05	Toray Industries	Derivado de 2,3-di-hidro-1h-inden-2-il-ureia e sua aplicação farmacêutica
EP2322176A1 (fr)	2009-11-11	2011-05-18	Almirall, S.A.	Nouveaux dérivés de 7-phényl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one
WO2011065800A2 (fr) *	2009-11-30	2011-06-03	주식회사 오스코텍	Dérivé de pyrimidine, procédé de préparation de ce dérivé et composition pharmaceutique contenant ce dérivé
WO2012088266A2 (fr)	2010-12-22	2012-06-28	Incyte Corporation	Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
CN102816162B (zh) *	2011-06-10	2016-04-27	中国科学院广州生物医药与健康研究院	嘧啶并嘧啶酮类化合物及其药用组合物和应用
US9611267B2 (en)	2012-06-13	2017-04-04	Incyte Holdings Corporation	Substituted tricyclic compounds as FGFR inhibitors
DK2872491T3 (da) *	2012-07-11	2021-08-09	Blueprint Medicines Corp	Inhibitorer af fibroblastvækstfaktorreceptoren
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
EP3943087A1 (fr)	2013-03-15	2022-01-26	Celgene CAR LLC	Composés hétéroaryle et utilisations associées
US9321786B2 (en)	2013-03-15	2016-04-26	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
TWI649318B (zh)	2013-04-19	2019-02-01	英塞特控股公司	作為ｆｇｆｒ抑制劑之雙環雜環
BR112016008849B8 (pt)	2013-10-25	2022-09-06	Blueprint Medicines Corp	Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas
MA38393B1 (fr)	2014-03-13	2018-11-30	Sanofi Sa	Composés hétéroaryle et utilisations associées
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
AU2016219822B2 (en)	2015-02-20	2020-07-09	Incyte Holdings Corporation	Bicyclic heterocycles as FGFR inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (fr)	2015-02-20	2016-08-25	Incyte Corporation	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2017031116A1 (fr) *	2015-08-18	2017-02-23	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Inhibiteurs de ku70/80 à petites molécules et utilisations associées
WO2018004258A1 (fr) *	2016-06-28	2018-01-04	한미약품 주식회사	Nouveau dérivé hétérocyclique et son utilisation
KR20180002053A (ko) *	2016-06-28	2018-01-05	한미약품 주식회사	신규한 헤테로시클릭 유도체 화합물 및 이의 용도
US11241435B2 (en) *	2016-09-16	2022-02-08	The General Hospital Corporation	Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
US11285158B2 (en)	2017-02-28	2022-03-29	The General Hospital Corporation	Uses of pyrimidopyrimidinones as SIK inhibitors
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
JP2021501130A (ja)	2017-10-05	2021-01-14	フルクラムセラピューティクス，インコーポレイテッド	ＤＵＸ４の発現を低減するためのｐ３８阻害剤の使用
TW201946630A (zh)	2018-05-04	2019-12-16	美商英塞特公司	Fgfr抑制劑之鹽
ES2991427T3 (es)	2018-05-04	2024-12-03	Incyte Corp	Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas
US20220098203A1 (en) *	2018-12-27	2022-03-31	Les Laboratoires Servier Sas	Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (fr)	2019-07-09	2021-01-14	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
WO2021067374A1 (fr)	2019-10-01	2021-04-08	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
GEAP202415945A (en)	2019-10-14	2024-04-25	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (fr)	2019-10-16	2021-04-22	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
GB201915828D0 (en)	2019-10-31	2019-12-18	Cancer Research Tech Ltd	Compounds, compositions and therapeutic uses thereof
AU2020395185A1 (en)	2019-12-04	2022-06-02	Incyte Corporation	Derivatives of an FGFR inhibitor
CA3163875A1 (fr)	2019-12-04	2021-06-10	Incyte Corporation	Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
WO2021146424A1 (fr)	2020-01-15	2021-07-22	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
EP4323405A1 (fr)	2021-04-12	2024-02-21	Incyte Corporation	Polythérapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4
AR126101A1 (es)	2021-06-09	2023-09-13	Incyte Corp	Heterociclos tricíclicos como inhibidores de fgfr
CA3220274A1 (fr)	2021-06-09	2022-12-15	Incyte Corporation	Heterocycles tricycliques en tant qu'inhibiteurs de fgfr

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8814352D0 (en)	1988-06-16	1988-07-20	Smith Kline French Lab	Chemical compounds
IL117923A (en)	1995-05-03	2000-06-01	Warner Lambert Co	Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US6147080A (en) *	1996-12-18	2000-11-14	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
PL340412A1 (en) *	1997-10-20	2001-01-29	Hoffmann La Roche	Bicyclic kinase inhibitors
EE200000706A (et) *	1998-05-26	2002-06-17	Warner-Lambert Company	Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid
HK1041483B (zh)	1998-10-23	2004-12-24	霍夫曼-拉罗奇有限公司	雙環氮雜環

2000
- 2000-10-13 KR KR10-2002-7005031A patent/KR100523120B1/ko not_active Expired - Fee Related
- 2000-10-13 YU YU29102A patent/YU29102A/sh unknown
- 2000-10-13 AU AU77873/00A patent/AU776250B2/en not_active Ceased
- 2000-10-13 NZ NZ518119A patent/NZ518119A/en unknown
- 2000-10-13 MX MXPA02003950A patent/MXPA02003950A/es active IP Right Grant
- 2000-10-13 PL PL00357502A patent/PL357502A1/xx not_active Application Discontinuation
- 2000-10-13 EP EP00967864A patent/EP1228070B1/fr not_active Expired - Lifetime
- 2000-10-13 DE DE60033307T patent/DE60033307T2/de not_active Expired - Fee Related
- 2000-10-13 AT AT00967864T patent/ATE353329T1/de not_active IP Right Cessation
- 2000-10-13 HU HU0203564A patent/HUP0203564A3/hu unknown
- 2000-10-13 TR TR2002/01057T patent/TR200201057T2/xx unknown
- 2000-10-13 WO PCT/EP2000/010088 patent/WO2001029042A1/fr not_active Ceased
- 2000-10-13 ES ES00967864T patent/ES2280247T3/es not_active Expired - Lifetime
- 2000-10-13 CA CA002388142A patent/CA2388142C/fr not_active Expired - Fee Related
- 2000-10-13 IL IL14910000A patent/IL149100A0/xx unknown
- 2000-10-13 CN CNB008146624A patent/CN1171889C/zh not_active Expired - Fee Related
- 2000-10-13 CZ CZ20021744A patent/CZ20021744A3/cs unknown
- 2000-10-13 RU RU2002112753/04A patent/RU2265606C2/ru not_active IP Right Cessation
- 2000-10-13 HR HR20020328A patent/HRP20020328A2/hr not_active Application Discontinuation
- 2000-10-13 BR BR0015243-9A patent/BR0015243A/pt not_active IP Right Cessation
- 2000-10-13 JP JP2001531840A patent/JP3961830B2/ja not_active Expired - Fee Related
- 2000-10-17 PE PE2000001104A patent/PE20010758A1/es not_active Application Discontinuation
- 2000-10-19 AR ARP000105489A patent/AR026084A1/es not_active Application Discontinuation
- 2000-10-20 US US09/693,337 patent/US6451804B1/en not_active Expired - Fee Related
2002
- 2002-04-16 NO NO20021781A patent/NO20021781L/no not_active Application Discontinuation
- 2002-04-19 MA MA26612A patent/MA26837A1/fr unknown

Also Published As

Publication number	Publication date
AU776250B2 (en)	2004-09-02
CA2388142C (fr)	2008-12-09
NO20021781D0 (no)	2002-04-16
PL357502A1 (en)	2004-07-26
HUP0203564A3 (en)	2004-07-28
HRP20020328A2 (en)	2004-02-29
WO2001029042A1 (fr)	2001-04-26
EP1228070A1 (fr)	2002-08-07
AU7787300A (en)	2001-04-30
HUP0203564A2 (hu)	2003-02-28
JP3961830B2 (ja)	2007-08-22
NZ518119A (en)	2004-02-27
HK1051039A1 (en)	2003-07-18
US6451804B1 (en)	2002-09-17
CZ20021744A3 (cs)	2002-08-14
MXPA02003950A (es)	2002-10-23
PE20010758A1 (es)	2001-07-21
BR0015243A (pt)	2002-07-16
ATE353329T1 (de)	2007-02-15
RU2265606C2 (ru)	2005-12-10
CN1171889C (zh)	2004-10-20
JP2003512378A (ja)	2003-04-02
CN1382144A (zh)	2002-11-27
TR200201057T2 (tr)	2002-09-23
RU2002112753A (ru)	2004-01-20
DE60033307D1 (en)	2007-03-22
YU29102A (sh)	2004-12-31
IL149100A0 (en)	2002-11-10
KR20020038963A (ko)	2002-05-24
AR026084A1 (es)	2002-12-26
NO20021781L (no)	2002-04-18
EP1228070B1 (fr)	2007-02-07
ES2280247T3 (es)	2007-09-16
DE60033307T2 (de)	2007-07-12
KR100523120B1 (ko)	2005-10-20
CA2388142A1 (fr)	2001-04-26

Publication	Publication Date	Title
MA26837A1 (fr)	2004-12-20	Heterocycles azotes bicycliques heteroalky-lamino substitues en tant qu'inhibiteurs de kinase de proteine p38.
MA26836A1 (fr)	2004-12-20	Heterocycles azotes bicycliques alkylamino substitues en tant qu'inhibiteurs de kinase de proteine p38.
FR14C0055I2 (fr)	2016-06-10	Cyanoquinolines 3 substituees en tant qu'inhibiteurs de kinases de la proteine tyrosine
PT1218378E (pt)	2003-09-30	Derivados de terc-butil-(7-metil-imidazo-¬1,2-a\|-piridin-3-il)-amina
ATE236165T1 (de)	2003-04-15	Substituierte stickstoff enthaltende heterocyclen als p38 protein kinase inhibitoren
MA26819A1 (fr)	2004-12-20	Pteridinones servant d' inhibiteurs de kinases.
MA26831A1 (fr)	2004-12-20	Derives de benzodiazepine."
MA26932A1 (fr)	2004-12-20	Derives d'imidazole.
ATE322491T1 (de)	2006-04-15	Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
CO4910133A1 (es)	2000-04-24	Antagonistas de 5-h[1f]
ZA200202775B (en)	2004-02-25	Quinazoline derivatives as VEGF inhibitors.
ATE293618T1 (de)	2005-05-15	4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel
NL300242I1 (nl)	2006-12-01	Mega-carboxyaryl gesubstitueerde difenylureums alsraf kinaseremmers.
DE60126828D1 (de)	2007-04-05	"pyrazolverbindungen, die sich als proteinkinaseinhibitoren eignen"
NL300203I2 (nl)	2005-11-01	Antiviraal werkzame heterocyclische azahexaan-derivaten.
DE69718472D1 (de)	2003-02-20	Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
MA26824A1 (fr)	2004-12-20	5-(2-substitué-5-hétérocyclylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidine-7-ones servant d'inhibiteurs de phosphodiestérase.
MA27083A1 (fr)	2004-12-20	Derives de nicotine ou d'isonicotine benzothiazole
MA25493A1 (fr)	2002-07-01	Derives de 3(5)-amino-pyrazole, procede pour leur preparation et leur utilisation en tant qu'agents antitumoraux.
DE60214428D1 (de)	2006-10-12	1, 4-dihydro-1, 4-diphenylpyridin-derivate
CU23053A3 (es)	2005-06-24	1,2,3,4-tetrahidroquinlinas 2-sustituidas 4-amino sustituidas
IS5715A (is)	2001-05-31	Aðferð til smíði á 4-karboxýamínó-2-setnu-1,2,3,4-tetrahýdrókínólíni
DE60009888D1 (de)	2004-05-19	Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen
ATE387448T1 (de)	2008-03-15	4,5-pyrazinoxindole als proteinkinasehemmer
FI962639L (fi)	1996-06-26	Diaryyli-5,6-fuusioituneita heterosyklisiä happoja leukotrieeniantagonisteina